D. G. Tandefelt

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study

D. Amadori, D. Dearnaley, M. Climent, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Plasma AR and abiraterone-resistant prostate cancer

Delila Gasi Tandefelt, D. Amadori, F. Demichelis, 2015, Science Translational Medicine.

Circulating cell-free DNA: Translating prostate cancer genomics into clinical care.

Delila Gasi Tandefelt, J. Bono, D. G. Tandefelt, 2020 .

Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer

Delila Gasi Tandefelt, E. Scarpi, F. Demichelis, 2020, British Journal of Cancer.

Introducing PIONEER: a project to harness big data in prostate cancer research

Delila Gasi Tandefelt, C. Auffray, H. Huisman, 2020, Nature Reviews Urology.